Abstract: The present invention is for a formulation comprising a nucleic acid vaccine and an immunoenhancing amount of acemannan, whereby the acemannan enhances immune response, in a host, to the vaccine. The present invention is also for a method of enhancing the immune response of a host to a nucleic acid vaccine by administering a formulation comprising a nucleic acid vaccine and acemannan.

Abstract: The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.